|
1）Kume H, Yamazaki T, Togano T, et al. Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan. Med Mycol J. 2011; 52: 117-27
|
|
|
|
2）深在性真菌症ガイドライン作成委員会，編．深在性真菌症の診断・治療ガイドライン2014．東京：協和企画；2014
|
|
|
|
|
|
3）Pauw BD, Walsh TJ, Donelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46: 1813
|
|
|
|
|
4）Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis. 2007; 44: 1329
|
|
|
|
|
|
5）Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008; 177: 27-34
|
|
|
|
|
|
6）Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009; 49: 1688-93
|
|
|
|
|
|
7）Avni T, Levy I, Sprecher H, et al. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review J Clin Microbiol. 2012; 50: 3652-8
|
|
|
|
|
|
8）Thornton C. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol. 2008; 15: 1095-105
|
|
|
|
|
|
9）White PL, Parr C, Thornton C, et al. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol. 2013; 51: 1510-6
|
|
|
|
|
|
10）Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408-15
|
|
|
|
|
|
11）Cornely OA, Maertens J, Bresnik M, et al. AmBiLoad Trial Study Group: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007; 44: 1289-97
|
|
|
|
|
|
12）Marr KA, Schlamm H, Rottinghaus ST, et al. A randomized, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 2012, London
|
|
|
|
|
|
13）Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007; 110: 2740-6
|
|
|
|
|
|
14）Tashiro T, Izumikawa K, Tashiro M, et al. A case series of chronic necrotizing pulmonary aspergillosis and a new proposal. Jpn J Infect Dis. 2013; 66: 312-6
|
|
|
|
|
|
15）Izumikawa K, Tashiro T, Tashiro M, et al. Pathogenesis and clinical features of chronic pulmonary aspergillosis - Is it possible to distinguish CNPA and CCPA clinically? J Infect Chemother. 2014; 20: 208-12
|
|
|
|
|
|
16）Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010; 61: 410-8
|
|
|
|
|
|
17）Kohno S, Izumikawa K, Yoshida M, et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis. 2013; 32: 387-97
|
|
|
|
|
|
18）Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis. 2012; 31: 3231-9
|
|
|
|
|
|
19）Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis. 2010; 51: 1383-91
|
|
|
|
|
|
20）Tashiro M, Izumikawa K, Minematsu A, et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother. 2012; 56: 584-7
|
|
|
|
|
|
21）Kikuchi K, Watanabe A, Ito J, et al. Antifungal susceptibility of Aspergillus fumigatus clinical isolates collected from various areas in Japan. J Infect Chemother. 2014; 20: 336-8
|
|
|
|
|
|
22）Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009; 9: 789-95
|
|
|
|
|
|
23）Tashiro M, Izumikawa K, Hirano K, et al. Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother. 2012; 56: 4870-5
|
|
|
|
|
|
24）Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007; 45: 1610-7
|
|
|
|
|
|
25）Katragkou A, Tsikopoulou F, Roilides E, et al. Mycoses. Posaconazole: when and how? The clinician’s view. Mycoses. 2012; 55: 110-22
|
|
|
|
|
|
26）Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009; 48: 1743-51
|
|
|
|
|
|
27）Ullmann AJ, Shoham S, Huang W, et al. A phase 3 randomized, double-blind, non-inferiority trial evaluating isavuconazole (ISA) vs. voriconazole (VRC) for the primary treatment of invasive fungal disease (IFD) caused by Aspergillus spp. or other filamentous fungi (SECURE): outcomes by malignancy. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (2014), poster No. M-1756
|
|
|
|
|
|
28）Datta K, Rhee P, Byrnes E 3rd, et al. Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J Clin Microbiol. 2013; 51: 3090-3
|
|
|
|
|
|
29）Gregson L, Goodwin J, Johnson A, et al. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. Antimicrob Agents Chemother. 2013; 57: 5778-80
|
|
|
|
|
|
30）Pfaller MA, Messer SA, Motyl MR, et al. In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother. 2013; 57: 1065-8
|
|
|
|
|